Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.

Caritis SN, Simhan HN, Zhao Y, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM Jr, Sorokin Y, Carpenter M, Lo J, Ramin SM, Harper M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

Am J Obstet Gynecol. 2012 Nov;207(5):396.e1-8. doi: 10.1016/j.ajog.2012.08.001. Epub 2012 Aug 6.

2.

Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Caritis SN, Sharma S, Venkataramanan R, Rouse DJ, Peaceman AM, Sciscione A, Spong CY, Varner MW, Malone FD, Iams JD, Mercer BM, Thorp JM Jr, Sorokin Y, Carpenter M, Lo J, Ramin S, Harper M; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

Am J Obstet Gynecol. 2011 Jul;205(1):40.e1-8. doi: 10.1016/j.ajog.2011.03.028. Epub 2011 Mar 22.

3.

Effect of 17-alpha hydroxyprogesterone caproate on cervical length in twin pregnancies.

Lim AC, Schuit E, Papatsonis D, van Eyck J, Porath MM, van Oirschot CM, Hummel P, Hasaart TH, Kleiverda G, de Graaf IM, van Ginkel AA, Mol BW, Bruinse HW.

Ultrasound Obstet Gynecol. 2012 Oct;40(4):426-30. doi: 10.1002/uog.11174.

4.

17-hydroxy progesterone caproate for preterm labor prevention: final blood levels.

Usta IM, Usta J, Nassar AH.

Am J Obstet Gynecol. 2013 Apr;208(4):337. doi: 10.1016/j.ajog.2012.12.032. Epub 2013 Jan 4. No abstract available.

PMID:
23295976
5.

Does 17-α-hydroxyprogesterone caproate affect fetal biometry and birth weight in twin pregnancy?

Mulder EJ, Versteegh EM, Bloemenkamp KW, Lim AC, Mol BW, Bekedam DJ, Kwee A, Bruinse HW, Christiaens GC.

Ultrasound Obstet Gynecol. 2013 Sep;42(3):329-34. doi: 10.1002/uog.12486. Epub 2013 Aug 4.

6.

Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.

O'Brien JM, Lewis DF.

Am J Obstet Gynecol. 2016 Jan;214(1):45-56. doi: 10.1016/j.ajog.2015.10.934. Epub 2015 Nov 10. Review.

PMID:
26558340
7.

Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.

Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).

Am J Obstet Gynecol. 2016 Mar;214(3):376.e1-8. doi: 10.1016/j.ajog.2015.12.010. Epub 2015 Dec 12.

8.

A randomised controlled double-blind clinical trial of 17-hydroxyprogesterone caproate for the prevention of preterm birth in twin gestation (PROGESTWIN): evidence for reduced neonatal morbidity.

Awwad J, Usta IM, Ghazeeri G, Yacoub N, Succar J, Hayek S, Saasouh W, Nassar AH.

BJOG. 2015 Jan;122(1):71-9. doi: 10.1111/1471-0528.13031. Epub 2014 Aug 27.

9.

Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.

Manuck TA, Lai Y, Meis PJ, Dombrowski MP, Sibai B, Spong CY, Rouse DJ, Durnwald CP, Caritis SN, Wapner RJ, Mercer BM, Ramin SM.

Am J Obstet Gynecol. 2011 Aug;205(2):135.e1-9. doi: 10.1016/j.ajog.2011.03.048. Epub 2011 Apr 8.

10.

Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial.

Tan PC, King AS, Vallikkannu N, Omar SZ.

Arch Gynecol Obstet. 2012 Mar;285(3):585-90. doi: 10.1007/s00404-011-2026-3. Epub 2011 Jul 28.

PMID:
21796421
11.

Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.

Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM Jr, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network.

Am J Obstet Gynecol. 2014 Feb;210(2):128.e1-6. doi: 10.1016/j.ajog.2013.10.008. Epub 2013 Oct 7.

12.

Association of 17α-Hydroxyprogesterone Caproate and Risk of Infection.

Mainiero AD, Rouse DJ, Lopes V, Hughes BL.

Obstet Gynecol. 2015 Jul;126(1):103-8. doi: 10.1097/AOG.0000000000000881.

PMID:
26241262
13.

Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.

Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, Iams JD, Wapner RJ, Varner M, Carpenter M, Lo J, Thorp J, Mercer BM, Sorokin Y, Harper M, Ramin S, Anderson G; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Maternal-Fetal Medicine Units Network (MFMU).

Obstet Gynecol. 2009 Feb;113(2 Pt 1):285-92. doi: 10.1097/AOG.0b013e318193c677.

14.

Reply: To PMID 23295976.

Caritis SN.

Am J Obstet Gynecol. 2013 Apr;208(4):337-8. doi: 10.1016/j.ajog.2012.12.033. Epub 2013 Jan 4. No abstract available.

PMID:
23295980
15.

Pharmacology and placental transport of 17-hydroxyprogesterone caproate in singleton gestation.

Caritis SN, Sharma S, Venkataramanan R, Hankins GD, Miodovnik M, Hebert MF, Umans JG, Benedetti T, Mattison D, Zajicek A, Fischer D, Jackson A; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetrical-Fetal Pharmacology Research Units Network.

Am J Obstet Gynecol. 2012 Nov;207(5):398.e1-8. doi: 10.1016/j.ajog.2012.08.015. Epub 2012 Aug 16.

16.

Prevention of preterm delivery by 17 alpha-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial.

Senat MV, Porcher R, Winer N, Vayssière C, Deruelle P, Capelle M, Bretelle F, Perrotin F, Laurent Y, Connan L, Langer B, Mantel A, Azimi S, Rozenberg P; Groupe de Recherche en Obstétrique et Gynécologie.

Am J Obstet Gynecol. 2013 Mar;208(3):194.e1-8. doi: 10.1016/j.ajog.2013.01.032.

PMID:
23433324
17.

The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.

Durnwald CP, Lynch CD, Walker H, Iams JD.

Am J Obstet Gynecol. 2009 Oct;201(4):410.e1-5. doi: 10.1016/j.ajog.2009.07.009. Epub 2009 Aug 28.

18.

The effect of intramuscular progesterone on the rate of cervical shortening.

Pessel C, Moni S, Zork N, Brubaker S, Vink J, Fuchs K, Nhan-Chang CL, Ananth CV, Gyamfi-Bannerman C.

Am J Obstet Gynecol. 2013 Sep;209(3):269.e1-7. doi: 10.1016/j.ajog.2013.05.027. Epub 2013 Jun 6.

PMID:
23747451
19.

17α-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial.

Lim AC, Schuit E, Bloemenkamp K, Bernardus RE, Duvekot JJ, Erwich JJ, van Eyck J, Groenwold RH, Hasaart TH, Hummel P, Kars MM, Kwee A, van Oirschot CM, van Pampus MG, Papatsonis D, Porath MM, Spaanderman ME, Willekes C, Wilpshaar J, Mol BW, Bruinse HW.

Obstet Gynecol. 2011 Sep;118(3):513-20. doi: 10.1097/AOG.0b013e31822ad6aa.

PMID:
21860279
20.

The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.

Gyamfi C, Horton AL, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Meis PJ, Spong CY, Dombrowski M, Sibai B, Varner MW, Iams JD, Mercer BM, Carpenter MW, Lo J, Ramin SM, O'Sullivan MJ, Miodovnik M, Conway D; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.

Am J Obstet Gynecol. 2009 Oct;201(4):392.e1-5. doi: 10.1016/j.ajog.2009.06.036. Epub 2009 Aug 29.

Supplemental Content

Support Center